129 related articles for article (PubMed ID: 15772070)
1. Structure of human cyclophilin A in complex with the novel immunosuppressant sanglifehrin A at 1.6 A resolution.
Kallen J; Sedrani R; Zenke G; Wagner J
J Biol Chem; 2005 Jun; 280(23):21965-71. PubMed ID: 15772070
[TBL] [Abstract][Full Text] [Related]
2. Sanglifehrin-cyclophilin interaction: degradation work, synthetic macrocyclic analogues, X-ray crystal structure, and binding data.
Sedrani R; Kallen J; Martin Cabrejas LM; Papageorgiou CD; Senia F; Rohrbach S; Wagner D; Thai B; Jutzi Eme AM; France J; Oberer L; Rihs G; Zenke G; Wagner J
J Am Chem Soc; 2003 Apr; 125(13):3849-59. PubMed ID: 12656618
[TBL] [Abstract][Full Text] [Related]
3. Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action.
Zenke G; Strittmatter U; Fuchs S; Quesniaux VF; Brinkmann V; Schuler W; Zurini M; Enz A; Billich A; Sanglier JJ; Fehr T
J Immunol; 2001 Jun; 166(12):7165-71. PubMed ID: 11390463
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes.
Huai Q; Kim HY; Liu Y; Zhao Y; Mondragon A; Liu JO; Ke H
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12037-42. PubMed ID: 12218175
[TBL] [Abstract][Full Text] [Related]
5. Sanglifehrin A, a novel cyclophilin-binding immunosuppressant, inhibits IL-2-dependent T cell proliferation at the G1 phase of the cell cycle.
Zhang LH; Liu JO
J Immunol; 2001 May; 166(9):5611-8. PubMed ID: 11313401
[TBL] [Abstract][Full Text] [Related]
6. Novel combinational treatment of cisplatin with cyclophilin A inhibitors in human heptocellular carcinomas.
Lee J
Arch Pharm Res; 2010 Sep; 33(9):1401-9. PubMed ID: 20945139
[TBL] [Abstract][Full Text] [Related]
7. Cyclophilin sensitivity to sanglifehrin A can be correlated to the same specific tryptophan residue as cyclosporin A.
Pemberton TJ; Kay JE
FEBS Lett; 2003 Dec; 555(2):335-40. PubMed ID: 14644438
[TBL] [Abstract][Full Text] [Related]
8. The novel cyclophilin-binding drug sanglifehrin A specifically affects antigen uptake receptor expression and endocytic capacity of human dendritic cells.
Woltman AM; Schlagwein N; van der Kooij SW; van Kooten C
J Immunol; 2004 May; 172(10):6482-9. PubMed ID: 15128841
[TBL] [Abstract][Full Text] [Related]
9. Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A.
Clarke SJ; McStay GP; Halestrap AP
J Biol Chem; 2002 Sep; 277(38):34793-9. PubMed ID: 12095984
[TBL] [Abstract][Full Text] [Related]
10. Enantioselective Synthesis and Biological Evaluation of Sanglifehrin A and B and Analogs.
Chang CF; Flaxman HA; Woo CM
Angew Chem Int Ed Engl; 2021 Jul; 60(31):17045-17052. PubMed ID: 34014025
[TBL] [Abstract][Full Text] [Related]
11. Cutting edge: sanglifehrin A, a novel cyclophilin-binding immunosuppressant blocks bioactive IL-12 production by human dendritic cells.
Steinschulte C; Taner T; Thomson AW; Bein G; Hackstein H
J Immunol; 2003 Jul; 171(2):542-6. PubMed ID: 12847216
[TBL] [Abstract][Full Text] [Related]
12. Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. II. Structure elucidation, stereochemistry and physico-chemical properties.
Fehr T; Kallen J; Oberer L; Sanglier JJ; Schilling W
J Antibiot (Tokyo); 1999 May; 52(5):474-9. PubMed ID: 10480571
[TBL] [Abstract][Full Text] [Related]
13. Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. I. Taxonomy, fermentation, isolation and biological activity.
Sanglier JJ; Quesniaux V; Fehr T; Hofmann H; Mahnke M; Memmert K; Schuler W; Zenke G; Gschwind L; Maurer C; Schilling W
J Antibiot (Tokyo); 1999 May; 52(5):466-73. PubMed ID: 10480570
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporin A and sanglifehrin A enhance chemotherapeutic effect of cisplatin in C6 glioma cells.
Han X; Yoon SH; Ding Y; Choi TG; Choi WJ; Kim YH; Kim YJ; Huh YB; Ha J; Kim SS
Oncol Rep; 2010 Apr; 23(4):1053-62. PubMed ID: 20204291
[TBL] [Abstract][Full Text] [Related]
15. Computational full electron structure study of biological activity in Cyclophilin A.
Zhou W; Rossetto AM; Pang X; Zhou L
J Biomol Struct Dyn; 2016; 34(4):870-6. PubMed ID: 26264861
[TBL] [Abstract][Full Text] [Related]
16. A proposed molecular model for the interaction of calcineurin with the cyclosporin A-cyclophilin A complex.
Ivery MT
Bioorg Med Chem; 1999 Jul; 7(7):1389-402. PubMed ID: 10465413
[TBL] [Abstract][Full Text] [Related]
17. The molecular replacement solution and X-ray refinement to 2.8 A of a decameric complex of human cyclophilin A with the immunosuppressive drug cyclosporin A.
Pflügl GM; Kallen J; Jansonius JN; Walkinshaw MD
J Mol Biol; 1994 Dec; 244(4):385-409. PubMed ID: 7990129
[TBL] [Abstract][Full Text] [Related]
18. Dentritic cell derived IL-18 production is inhibited by rapamycin and sanglifehrin A, but not cyclosporine A.
Ko H; Hambly BD; Eris JM; Levidiotis V; Wyburn K; Wu H; Chadban SJ; Yin JL
Transpl Immunol; 2008 Nov; 20(1-2):99-105. PubMed ID: 18662782
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive activity of the immunophilin-binding drug Sanglifehrin A in human whole blood: potent inhibition of interleukin-6 produced by lymphocytes and monocytes.
Härtel C; Iblher P; Puzik A; Wortmeier K; Ebel B; Schultz C; Müller-Steinhardt M
Scand J Immunol; 2006 Jan; 63(1):26-34. PubMed ID: 16398698
[TBL] [Abstract][Full Text] [Related]
20. Crystal structures of cyclophilin A complexed with cyclosporin A and N-methyl-4-[(E)-2-butenyl]-4,4-dimethylthreonine cyclosporin A.
Ke H; Mayrose D; Belshaw PJ; Alberg DG; Schreiber SL; Chang ZY; Etzkorn FA; Ho S; Walsh CT
Structure; 1994 Jan; 2(1):33-44. PubMed ID: 8075981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
